Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid,
rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to …

Drug resistant tuberculosis contributes significantly to the global burden of antimicrobial
resistance, often consuming a large proportion of the healthcare budget and associated …

Even if major improvements in therapeutic regimens and treatment outcomes have been
progressively achieved, tuberculosis (TB) remains the leading cause of death from a single …

Due to its high early bactericidal activity, isoniazid (INH) plays an essential role in
tuberculosis treatment. Genetic polymorphisms of N-acetyltransferase type 2 (NAT2) cause a …

Tuberculosis (TB) drug development has made substantial progress in the past decade.
There are currently at least ten drugs being evaluated in clinical trials. Some belong to …

Since standardized rifampin‐based first‐line regimens and fluoroquinolone‐based second‐
line regimens were used to treat tuberculosis (TB), unfortunately without timely modification …

The first nonclinical drug development tool (DDT) advanced by the Critical Path to TB Drug
Regimens (CPTR) Initiative through a regulatory review process has been endorsed by …

The emerge of drug-resistant tuberculosis (TB) strain in recent decades is hampering the
efforts of the international community to eliminate the disease worldwide. The World Health …

Background Novel drug regimens are needed for tuberculosis (TB) treatment. New regimens
aim to improve on characteristics such as duration, efficacy, and safety profile, but no single …

Background Rifampin-resistant and/or multidrug-resistant tuberculosis (RR/MDR-TB)
treatment requires multiple drugs, and outcomes remain suboptimal. Some drugs are …